SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -62.40% | -100.00% | -100.00% | +0.00% | -100.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +56.27% | +0.54% | +0.43% | +15.14% | +108.51% |
| Weighted Average Shares Diluted Growth | +56.27% | +0.54% | +0.43% | +740.95% | +562.28% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | -88.93% | -100.00% | +476.99% | +1622.83% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -47.35% | -46.59% | -51.32% | +241.00% | +291.01% |
| Book Value per Share Growth | -71.00% | -59.69% | -74.06% | +288.52% | +179.78% |
| Debt Growth | -20.96% | +24.43% | +20.14% | +36.88% | +27.45% |
| R&D Expense Growth | +77.56% | -6.02% | +2.89% | +14.27% | +40.61% |
| SG&A Expenses Growth | -88.52% | +5.93% | +3.51% | +47.66% | +195.22% |